Weighing the GLP-1 Market
- Forfatter
- Afsnit
- 465
- Udgivet
- 23. apr. 2024
- Forlag
- 0 Anmeldelser
- 0
- Afsnit
- 465 of 643
- Længde
- 24M
- Sprog
- Engelsk
- Format
- Kategori
- Økonomi & Business
The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health. If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy. Learn more about your ad choices. Visit megaphone.fm/adchoices
Other podcasts you might like ...
- The Journal.The Wall Street Journal & Spotify Studios
- The Can Do WayTheCanDoWay
- HW News Business Tit-BitsHW News Network
- 1,5 graderAndreas Bäckäng
- Self-Compassionate ProfessorPhD
- Networth and Chill with Your Rich BFFVivian Tu
- Don't Be SourMaxx Chewning
- Mark My Words PodcastMark Homer
- EGO NetCastMartin Lindeskog
- The Pathless Path with Paul MillerdPaul Millerd
- The Journal.The Wall Street Journal & Spotify Studios
- The Can Do WayTheCanDoWay
- HW News Business Tit-BitsHW News Network
- 1,5 graderAndreas Bäckäng
- Self-Compassionate ProfessorPhD
- Networth and Chill with Your Rich BFFVivian Tu
- Don't Be SourMaxx Chewning
- Mark My Words PodcastMark Homer
- EGO NetCastMartin Lindeskog
- The Pathless Path with Paul MillerdPaul Millerd
